PMID- 3969370
OWN - NLM
STAT- MEDLINE
DCOM- 19850306
LR  - 20190912
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 6
IP  - 1
DP  - 1985
TI  - DHT in prostate cancer tissue--a guide to management and therapy.
PG  - 19-25
AB  - In 24 untreated stage D2 prostate cancer patients with prostate DHT levels 
      greater than 2.5 ng/g, 20 initially responded to therapy with partial objective 
      progression (POR) or were objectively stable (OS) for 12 or more months while 
      four patients relapsed in less than 1 year. Of eight patients with prostate DHT 
      levels less than 2.0 ng/g, five had either objective progression or were 
      objectively stable for 6 months or less; two other patients have completed 
      remissions ranging from 16 to 24 months while one patient remains objectively 
      stable for 21 months to date. DHT concentrations were also measured in prostate 
      tissue of patients with advanced prostate cancer in relapse following either DES 
      or castration with or without estrogen therapy. Although castration, medical or 
      surgical, usually leads to DHT concentrations of less than 2.4 ng/g, two out of 
      20 surgical castrates and four out of nine estrogen-treated patients had values 
      above this level. These differences suggest that (1) increased tissue DHT levels 
      of DES-treated patients may be due to inadequate dosage or decreased compliance, 
      and (2) increased tissue DHT concentrations greater than 2.4 ng/g in castrates 
      suggests an adrenal cortical androgen contribution to the prostate DHT level. 
      These studies suggest that DHT measurements in prostate cancer tissue are of 
      value in predicting response in untreated prostate cancer patients and of 
      directing therapy in patients who are in relapse after orchiectomy or estrogen 
      therapy.
FAU - Geller, J
AU  - Geller J
FAU - Albert, J D
AU  - Albert JD
LA  - eng
GR  - CA 18003-08/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - EA6LD1M70M (Megestrol)
RN  - TJ2M0FR8ES (Megestrol Acetate)
SB  - IM
MH  - Castration
MH  - Diethylstilbestrol/therapeutic use
MH  - Dihydrotestosterone/*analysis
MH  - Humans
MH  - Male
MH  - Megestrol/analogs & derivatives/therapeutic use
MH  - Megestrol Acetate
MH  - Prognosis
MH  - Prostatic Neoplasms/*analysis/drug therapy/pathology
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1002/pros.2990060104 [doi]
PST - ppublish
SO  - Prostate. 1985;6(1):19-25. doi: 10.1002/pros.2990060104.